We’re working to ensure future dementia treatments reach people as quickly as possible.
We work with government bodies, the NHS and medicines regulators to plan ahead, so that future treatments will be made available to those who could benefit from them as soon as possible.
We want to make sure the UK is proactive and ambitious about identifying and adopting potential treatments for Alzheimer’s disease and other forms of dementia.
To overcome the potential barriers that could delay the roll-out of new treatments, we need researchers, pharmaceutical companies and the NHS to collaborate early in the development process.
Our animated video summarises the process that potential new treatments would have to go through before becoming available to people with dementia.
Addressing value and affordability
Our position on the outcomes from new treatments that are important to people and the side-effects they might be willing to risk.
Dementia treatments: what matters most to people
Our position on the outcomes from new treatments that are important to people and the side-effects they might be willing to risk.
Charity Medicines Access Coalition
We chair the Charity Medicines Access Coalition, working with charities from a range of different disease areas to resolve the challenges that can delay or prevent people from being able to access new treatments.
Addressing value and affordability
Following a workshop with stakeholders from the NHS, the National Institute for Health and Care Excellence (NICE), industry and academia, we examine the challenges and opportunities in assessing the value and affordability of new Alzheimer’s medicines.
Improving dementia treatment through data
We joined up with other dementia charities and the Royal College of Psychiatrists to explore how routine data collection in healthcare settings can shape access to and our understanding of future dementia treatments. Our briefing outlines how data collection for new dementia treatments should work in the UK.
Thinking Differently
We examine how the arrival of future dementia treatments could impact our health systems, highlighting the challenges of readying the NHS and balancing the value such treatments could bring to society against their affordability in increasingly difficult economic conditions.
Working with pharmaceutical industry
In all of our interactions with the pharmaceutical industry we act with the upmost integrity to ensure our independence and to accurately represent people living with dementia. Our position statement explains the policies that govern our work with pharmaceutical and biotech companies.
Are we ready to deliver disease-modifying treatments?
Our report emphasises the urgent need to ensure the health system is ready to deliver new treatments as soon as they become available.
Treatments of Tomorrow report
Our report outlines challenges and pressures in the healthcare system that may present problems for the roll-out of potential disease-modifying treatments of the future.
Get Involved with Policy
Get facts and stats
The facts and statistics around dementia in the UK, including prevalence, the impact on the economy and investment.
Policy Involvement Panel and Sounding Boards
Our panels of people affected by dementia help drive our policy work and policymakers understand the impact of dementia.
Campaign with us
With your support, we can make sure people living with dementia and research into the condition remain a national priority.
About our policy work
We're working with governments worldwide, funders, industry, and people impacted by dementia to support life-changing research.